207 related articles for article (PubMed ID: 19046881)
1. Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
Qiao JX; King SR; He K; Wong PC; Rendina AR; Luettgen JM; Xin B; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2009 Jan; 19(2):462-8. PubMed ID: 19046881
[TBL] [Abstract][Full Text] [Related]
2. 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Pinto DJ; Orwat MJ; Quan ML; Han Q; Galemmo RA; Amparo E; Wells B; Ellis C; He MY; Alexander RS; Rossi KA; Smallwood A; Wong PC; Luettgen JM; Rendina AR; Knabb RM; Mersinger L; Kettner C; Bai S; He K; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2006 Aug; 16(15):4141-7. PubMed ID: 16730984
[TBL] [Abstract][Full Text] [Related]
3. Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.
Quan ML; Han Q; Fevig JM; Lam PY; Bai S; Knabb RM; Luettgen JM; Wong PC; Wexler RR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1795-8. PubMed ID: 16434195
[TBL] [Abstract][Full Text] [Related]
4. Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications.
Qiao JX; Wang TC; Wang GZ; Cheney DL; He K; Rendina AR; Xin B; Luettgen JM; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2007 Sep; 17(18):5041-8. PubMed ID: 17643988
[TBL] [Abstract][Full Text] [Related]
5. Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
Orwat MJ; Qiao JX; He K; Rendina AR; Luettgen JM; Rossi KA; Xin B; Knabb RM; Wexler RR; Lam PY; Pinto DJ
Bioorg Med Chem Lett; 2014 Aug; 24(15):3341-5. PubMed ID: 24951330
[TBL] [Abstract][Full Text] [Related]
6. Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.
Shi Y; Sitkoff D; Zhang J; Han W; Hu Z; Stein PD; Wang Y; Kennedy LJ; O'Connor SP; Ahmad S; Liu EC; Seiler SM; Lam PY; Robl JA; Macor JE; Atwal KS; Zahler R
Bioorg Med Chem Lett; 2007 Nov; 17(21):5952-8. PubMed ID: 17855089
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.
Varnes JG; Wacker DA; Pinto DJ; Orwat MJ; Theroff JP; Wells B; Galemo RA; Luettgen JM; Knabb RM; Bai S; He K; Lam PY; Wexler RR
Bioorg Med Chem Lett; 2008 Jan; 18(2):749-54. PubMed ID: 18054227
[TBL] [Abstract][Full Text] [Related]
8. Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa.
Qiao JX; Cheney DL; Alexander RS; Smallwood AM; King SR; He K; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2008 Jul; 18(14):4118-23. PubMed ID: 18550370
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.
Corte JR; Fang T; Pinto DJ; Han W; Hu Z; Jiang XJ; Li YL; Gauuan JF; Hadden M; Orton D; Rendina AR; Luettgen JM; Wong PC; He K; Morin PE; Chang CH; Cheney DL; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2008 May; 18(9):2845-9. PubMed ID: 18424044
[TBL] [Abstract][Full Text] [Related]
10. Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa.
Kochanny MJ; Adler M; Ewing J; Griedel BD; Ho E; Karanjawala R; Lee W; Lentz D; Liang AM; Morrissey MM; Phillips GB; Post J; Sacchi KL; Sakata ST; Subramanyam B; Vergona R; Walters J; White KA; Whitlow M; Ye B; Zhao Z; Shaw KJ
Bioorg Med Chem; 2007 Mar; 15(5):2127-46. PubMed ID: 17227710
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of potent and selective factor Xa inhibitors: benzimidazole derivatives with the side chain oriented to the prime site of factor Xa.
Ueno H; Katoh S; Yokota K; Hoshi J; Hayashi M; Uchida I; Aisaka K; Hase Y; Cho H
Bioorg Med Chem Lett; 2004 Aug; 14(16):4281-6. PubMed ID: 15261287
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors.
Yoshikawa K; Yoshino T; Yokomizo Y; Uoto K; Naito H; Kawakami K; Mochizuki A; Nagata T; Suzuki M; Kanno H; Takemura M; Ohta T
Bioorg Med Chem Lett; 2011 Apr; 21(7):2133-40. PubMed ID: 21345673
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Pinto DJ; Orwat MJ; Koch S; Rossi KA; Alexander RS; Smallwood A; Wong PC; Rendina AR; Luettgen JM; Knabb RM; He K; Xin B; Wexler RR; Lam PY
J Med Chem; 2007 Nov; 50(22):5339-56. PubMed ID: 17914785
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).
Pruitt JR; Pinto DJ; Galemmo RA; Alexander RS; Rossi KA; Wells BL; Drummond S; Bostrom LL; Burdick D; Bruckner R; Chen H; Smallwood A; Wong PC; Wright MR; Bai S; Luettgen JM; Knabb RM; Lam PY; Wexler RR
J Med Chem; 2003 Dec; 46(25):5298-315. PubMed ID: 14640539
[TBL] [Abstract][Full Text] [Related]
15. Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand.
Nazaré M; Essrich M; Will DW; Matter H; Ritter K; Urmann M; Bauer A; Schreuder H; Czech J; Lorenz M; Laux V; Wehner V
Bioorg Med Chem Lett; 2004 Aug; 14(16):4197-201. PubMed ID: 15261269
[TBL] [Abstract][Full Text] [Related]
16. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: part 2.
Stürzebecher A; Dönnecke D; Schweinitz A; Schuster O; Steinmetzer P; Stürzebecher U; Kotthaus J; Clement B; Stürzebecher J; Steinmetzer T
ChemMedChem; 2007 Jul; 2(7):1043-53. PubMed ID: 17541992
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
[TBL] [Abstract][Full Text] [Related]
18. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1.
Quan ML; Liauw AY; Ellis CD; Pruitt JR; Carini DJ; Bostrom LL; Huang PP; Harrison K; Knabb RM; Thoolen MJ; Wong PC; Wexler RR
J Med Chem; 1999 Jul; 42(15):2752-9. PubMed ID: 10425086
[TBL] [Abstract][Full Text] [Related]
20. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
